Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.810
+0.130 (7.74%)
At close: Nov 20, 2026, 4:00 PM EST
1.870
+0.060 (3.31%)
After-hours: Nov 20, 2026, 7:59 PM EST
Pyxis Oncology Revenue
Pyxis Oncology had revenue of $11.04M in the twelve months ending September 30, 2026, up 291.42% year-over-year. In the year 2025, Pyxis Oncology had annual revenue of $13.86M, down -14.17%. That makes Pyxis Oncology the 36,956th largest company in the world by revenue and 4,834th in the United States.
Revenue (ttm)
$11.04M
Revenue Growth
+291.42%
P/S Ratio
19.61
Revenue / Employee
$197,107
Employees
56
Market Cap
216.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.86M | -2.29M | -14.17% |
| Dec 31, 2024 | 16.15M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 83.53M |
| vTv Therapeutics | 36.84M |
| AC Immune | 23.75M |
| Alpha Cognition | 20.20M |
| Lineage Cell Therapeutics | 10.84M |
| MediWound | 10.01M |
| Artiva Biotherapeutics | 251.00K |
PYXS News
- 2 days ago - Pyxis Oncology announces updated results from ongoing Phase 1 MICVO study - TheFly
- 2 days ago - William Blair upgrades Pyxis on head and neck cancer data - TheFly
- 2 days ago - Pyxis Oncology upgraded to Outperform from Market Perform at William Blair - TheFly
- 2 days ago - Pyxis Oncology Transcript: Study update - Transcripts
- 2 days ago - Pyxis Oncology Press release: Study update - Filings
- 2 days ago - Pyxis Oncology Slides: Study update - Filings
- 3 days ago - Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium - GlobeNewsWire
- 11 days ago - Pyxis Oncology Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts